Clinical Trials for Digestive Diseases

Currently registered clinical trials for Digestive Diseases from ClinicalTrials.gov. 20 recruiting, 50 total studies.

This content is for informational purposes only. Always consult a healthcare professional.

Source: ClinicalTrials.gov — U.S. National Library of Medicine — A database of privately and publicly funded clinical studies conducted around the world (U.S. National Library of Medicine, public domain).

This page lists clinical trials related to Digestive Diseases from the ClinicalTrials.gov database.

Trial Summary

  • Total studies: 50
  • Recruiting: 20
  • Active, not recruiting: 6
  • Completed: 13
  • Other: 11

Results are refreshed periodically and may not reflect the most current information available from ClinicalTrials.gov.

Recruiting Trials

NCT00027274 — Cancer in Inherited Bone Marrow Failure Syndromes

StatusRecruiting
PhaseN/A
SponsorNational Cancer Institute (NCI)
Enrollment4000
Study TypeOBSERVATIONAL
ConditionsDiamond Blackfan Anemia; Dyskeratosis Congenita; Fanconi Anemia; Shwachman Diamond Syndrome; Inherited Bone Marrow Failure Syndrome, Aplastic Anemia

Background:

A prospective cohort of Inherited Bone Marrow Failure Syndrome (IBMFS) will provide new information regarding cancer rates and types in these disorders.

Pathogenic variant(s) in IBMFS genes are relevant to carcinogenesis in sporadic cancers.

Patients with IBMFS who develop cancer differ in their genetic and/or environmental features from patients with IBMFS who do not develop can…

NCT00943514 — Natural History of Bronchiectasis

StatusRecruiting
PhaseN/A
SponsorNational Heart, Lung, and Blood Institute (NHLBI)
Enrollment900
Study TypeOBSERVATIONAL
ConditionsBronchiectasis; Cystic Fibrosis; Autoimmune Disease; Common Variable Immunodeficiency

Background:

  • Bronchiectasis is a disease characterized by airways that are inflamed, abnormally dilated, and chronically infected. Individuals with bronchiectasis have a history of chronic and recurring respiratory infections. Depending on the underlying cause, these infections may involve the entire respiratory tract, resulting in sinus, ear, and lung disease.
  • Bronchiectasis continues to b…

NCT01915225 — Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer

StatusRecruiting
PhaseN/A
SponsorNational Cancer Institute (NCI)
Enrollment1800
Study TypeOBSERVATIONAL
ConditionsColorectal Neoplasms; Gastric Neoplasms; Cholangiocarcinoma; Bile Duct Cancer; Pancreas Cancer

Background:

- Recent advances in cancer research have led to new therapies to treat the disease. It is important to continue these advances and discover new ones. To do that, researchers need tissue samples from solid tumors. This study will collect such samples from people already scheduled to have a procedure at the National Institutes of Health Clinical Center (NIHCC).

Objectives:

- To …

NCT03805919 — Men at High Genetic Risk for Prostate Cancer

StatusRecruiting
PhaseN/A
SponsorNational Cancer Institute (NCI)
Enrollment500
Study TypeOBSERVATIONAL
ConditionsProstatic Neoplasms

Background:

Research studies have shown that genetic changes and family history may increase a man s risk for prostate cancer. Researchers want to follow the prostate health of men who have specific genetic changes associated with prostate cancer to help them learn more about which men are at higher risk for prostate cancer.

Objectives:

To study men with specific genetic changes and determin…

NCT04222413 — Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

StatusRecruiting
PhasePhase 1
SponsorNational Cancer Institute (NCI)
Enrollment116
Study TypeINTERVENTIONAL
ConditionsAdvanced Solid Tumors; Metastatic Pancreatic Cancer; Pediatric Solid Tumor; Advanced Breast Cancer; Malignant Peripheral Nerve Sheath Tumor
Interventions

Background:

Metastasis is the spread of cancer from one organ to a nonadjacent organ. It causes 90% of cancer deaths. No treatment specifically prevents or reduces metastasis. Researchers hope a new drug can help. It stops cancer cells from growing and spreading further and possibly shrink cancer lesions in distant organs.

Objective:

To find a safe dose of metarrestin and to see if this dose…

NCT04509050 — Study to Evaluate Biological & Clinical Effects of Significantly Corrected CFTR Function in Infants & Young Children

StatusRecruiting
PhaseN/A
SponsorSonya Heltshe
Enrollment210
Study TypeOBSERVATIONAL
ConditionsCystic Fibrosis
Interventions

This is a two-part, multi-center, prospective longitudinal, exploratory study of highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators and their impact on children with cystic fibrosis (CF).

NCT04172532 — Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

StatusRecruiting
PhasePhase 1 / Phase 2
SponsorNational Cancer Institute (NCI)
Enrollment92
Study TypeINTERVENTIONAL
ConditionsLocally Advanced Pancreatic Adenocarcinoma; Stage III Pancreatic Cancer AJCC v8
Interventions; ;

This phase I/II trial studies the safety, side effects and best dose of M3814 and to see how well it works when given together with radiation therapy in treating patients with pancreatic cancer that has spread to nearby tissue or lymph nodes (locally advanced). M3814 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hypofractionated radiation therapy del…

NCT04847063 — Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies

StatusRecruiting
PhasePhase 1
SponsorNational Cancer Institute (NCI)
Enrollment60
Study TypeINTERVENTIONAL
ConditionsPeritoneal Mesothelioma; Peritoneal Carcinomatosis; Ovarian Cancer; Gastrointestinal Cancer; Appendiceal Cancer
Interventions; ;

Background:

Cytoreductive surgery (CRS) removes tumors in the abdomen. HIPEC is hyperthermic (heated) chemotherapy that washes the inside of the abdomen. CRS with HIPEC may help people with peritoneal carcinomatosis. These are tumors that have spread to the lining of the abdomen from other cancers. Researchers think they can improve the results of CRS with HIPEC treatment on these tumors by ch…

NCT05041374 — Evaluation of Patients With Gastrointestinal Disease

StatusRecruiting
PhaseN/A
SponsorNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Enrollment4000
Study TypeOBSERVATIONAL
ConditionsLower GI Disease; Gastrointestinal Diseases

Background:

Ongoing and future research projects that study gastrointestinal diseases depend on access to biological samples and clinical data. Researchers want to study people who are seen and treated for these diseases. This may help them assess and treat these diseases better in the future.

Objective:

To collect data and samples from people being seen and/or treated for gastrointestinal p…

NCT03481829 — Early Tracking of Childhood Health Determinants (ETCHED) Study

StatusRecruiting
PhaseN/A
SponsorNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Enrollment1500
Study TypeOBSERVATIONAL
ConditionsDiabetes Mellitus; Obesity; Fatty Liver

Background:

Children s weight has increased sharply in recent years. This may put them at higher risk for health problems. High blood glucose in a pregnant mother and too much weight gain during pregnancy also may have long-term effects on the child s health. Children who become overweight or obese during childhood tend to remain so as adults. Researchers want to study many risk factors during…

NCT06318169 — A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

StatusRecruiting
PhasePhase 3
Sponsor89bio, Inc.
Enrollment1350
Study TypeINTERVENTIONAL
ConditionsMetabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
Interventions;

The study will assess the efficacy and safety of 2 dose regimens of pegozafermin compared to placebo for the treatment of liver fibrosis stage F2 or F3 in adult participants with MASH.

NCT06045754 — A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn’s Disease

StatusRecruiting
PhasePhase 4
SponsorTakeda
Enrollment100
Study TypeINTERVENTIONAL
ConditionsCrohn’s Disease
Interventions; ;

The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with adalimumab or vedolizumab (VDZ) together with ustekinumab (UST) in adults with moderate to severe Crohn’s Disease, and the effect of treatment with vedolizumab alone, after the dual targeted treatment.

The study is conducted in two parts. In Part A, participants will receive the…

NCT06419374 — A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

StatusRecruiting
PhasePhase 3
Sponsor89bio, Inc.
Enrollment762
Study TypeINTERVENTIONAL
ConditionsMetabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
Interventions;

The study will assess the efficacy and safety of pegozafermin administered in participants with compensated cirrhosis due to MASH (biopsy-confirmed fibrosis stage F4 MASH [previously known as nonalcoholic steatohepatitis, NASH]).

NCT07691125 — Phase IV Study of rhGH Injection in Adult Short Bowel Syndrome

StatusRecruiting
PhasePhase 4
SponsorChangchun GeneScience Pharmaceutical Co., Ltd.
Enrollment100
Study TypeINTERVENTIONAL
ConditionsShort Bowel Syndrome (SBS) in Adults
Interventions

This is a multicenter, open-label, single-arm clinical trial. A total of 100 participants with short bowel syndrome (SBS) receiving parenteral nutrition (PN) support are planned to be enrolled. The trial includes a 2-week run-in phase and a 4-week intervention phase, during which participants will receive rhGH injections. A safety follow-up period will then be conducted through Week 52.

NCT06562192 — Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

StatusRecruiting
PhasePhase 1
SponsorNovartis Pharmaceuticals
Enrollment162
Study TypeINTERVENTIONAL
ConditionsPancreatic Ductal Adenocarcinoma; Non-small Cell Lung Cancer; HR+/HER2- Ductal and Lobular Breast Cancer; Triple Negative Breast Cancer; Colorectal Cancer
Interventions;

The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [177Lu]Lu-NNS309 and the safety and imaging properties of [68Ga]Ga-NNS309 in patients aged ≥ 18 years with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), HR+/HER2- ductal and lobular breast cancer (BC), triple negative breast c…

NCT06920043 — A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH

StatusRecruiting
PhasePhase 2
SponsorGlaxoSmithKline
Enrollment42
Study TypeINTERVENTIONAL
ConditionsMetabolic Dysfunction-Associated Steatohepatitis; Non-alcoholic Fatty Liver Disease
Interventions;

The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of efimosfermin in participants with metabolic dysfunction associated steatohepatitis (MASH) and compensated cirrhosis consistent with stage F4 fibrosis.

NCT06696768 — Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

StatusRecruiting
PhasePhase 1
SponsorNational Cancer Institute (NCI)
Enrollment24
Study TypeINTERVENTIONAL
ConditionsMetastatic Colorectal Adenocarcinoma; Stage III Colorectal Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Unresectable Colorectal Adenocarcinoma
Interventions; ;

This phase I trial studies the side effects and best dose of CA-4948 when given together with fluorouracil, leucovorin, oxaliplatin (FOLFOX) plus bevacizumab in treating patients with colorectal cancer that has spread from where it first started (primary site) to other places in the body (metastatic). CA-4948 may stop the growth of tumor cells by blocking some of the enzymes needed for cell gro…

NCT07459309 — Clinical Study on the Safety, Efficacy, and Exploration of Immune Mechanisms of a Combined Multimodal Tumor Therapy System for Hepatic Malignancies

StatusRecruiting
PhaseN/A
SponsorFudan University
Enrollment20
Study TypeINTERVENTIONAL
ConditionsLiver Cancer (Primary and Metastatic); Liver Ablation
Interventions

Clinical Study on the Safety, Efficacy, and Exploration of Immune Mechanisms of a Combined Multimodal Tumor Therapy System for Hepatic Malignancies

NCT07450547 — Phase 2 Study to Assess the Safety and Efficacy of ANG003

StatusRecruiting
PhasePhase 2
SponsorAnagram Therapeutics, Inc.
Enrollment113
Study TypeINTERVENTIONAL
ConditionsExocrine Pancreatic Insufficiency (EPI); Cystic Fibrosis (CF)
Interventions; ;

In this study, ANG003, a pancreatic enzyme replacement therapy (PERT; commonly called “enzymes”), is being investigated as a potential treatment for exocrine pancreatic insufficiency (EPI). People with EPI due to Cystic Fibrosis (CF) may be eligible to participate in this study. The primary objective of this study is to evaluate the safety of ANG003 and see if it works as well compared to Creon…

NCT06622057 — D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer

StatusRecruiting
PhasePhase 3
SponsorInnoPharmax Inc.
Enrollment240
Study TypeINTERVENTIONAL
ConditionsBiliary Tract Cancer (BTC)
Interventions; ;

The object of this trial is to evaluate the efficacy of D07001-softgel capsules + capecitabine compared with placebo + capecitabine by overall survival (OS).

Eligible patients with advanced biliary tract cancer (BTC) will be randomized (1:1:1) to receive either 60 mg D07001-softgel, 100 mg D07001-softgel, or placebo, combine with capecitabine. Treatment will be continued until disease progress…

Active, Not Recruiting

NCT02465060 — Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

StatusActive, not recruiting
PhasePhase 2
SponsorNational Cancer Institute (NCI)
Enrollment6452
Study TypeINTERVENTIONAL
ConditionsAdvanced Lymphoma; Advanced Malignant Solid Neoplasm; Bladder Carcinoma; Breast Carcinoma; Cervical Carcinoma
Interventions; ;

This phase II MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in patients with solid tumors, lymphomas, or multiple myelomas that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and does not respond to treatment (refractory). Patients must have progressed following at leas…

NCT03256773 — High Resolution Micro OCT Imaging

StatusActive, not recruiting
PhaseN/A
SponsorUniversity of Alabama at Birmingham
Enrollment160
Study TypeOBSERVATIONAL
ConditionsCystic Fibrosis; COPD; PCD - Primary Ciliary Dyskinesia; Covid19; Sinusitis

The purpose of this study is to learn about using the imaging to make images of the lungs and nose with the long-term goal of the research leading to potential treatments and new therapies for patients with cystic fibrosis.

NCT05500222 — A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)

StatusActive, not recruiting
PhasePhase 3
SponsorMadrigal Pharmaceuticals, Inc.
Enrollment845
Study TypeINTERVENTIONAL
ConditionsNASH; Cirrhosis, Liver
Interventions;

This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepatitis (NASH) cirrhosis by measuring the time to experiencing a Composite Clinical Outcome event.

NCT05628194 — ASSESSING THE GAY MALE EXPERIENCE WITH ANAL CANCER PREVENTION STRATEGIES

StatusActive, not recruiting
PhaseN/A
SponsorUniversity of Minnesota
Enrollment92
Study TypeOBSERVATIONAL
ConditionsAnal Cancer
Interventions

The purpose of this study is to describe current knowledge and opinions about anal cancer screening among men who have sex with men (MSM), as well as their experience receiving guideline-compliant care aimed at anal cancer risk reduction using a large-scale survey disseminated via social media.

NCT06497504 — Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)

StatusActive, not recruiting
PhasePhase 2
SponsorGlaxoSmithKline
Enrollment153
Study TypeINTERVENTIONAL
ConditionsHepatitis B
Interventions;

This study will evaluate the efficacy and safety of bepirovirsen compared to placebo in participants with human immunodeficiency virus (HIV)/hepatitis B virus (HBV) co-infection.

NCT06819813 — Project VIBE: Virtual Intervention for Binge Eating in Adolescents

StatusActive, not recruiting
PhaseN/A
SponsorUniversity of Pittsburgh
Enrollment50
Study TypeINTERVENTIONAL
ConditionsObesity; Binge-Eating Disorder; Binge Eating
Interventions

The aim of this project is to pilot test a novel mobile app intervention for adolescents with dysregulated eating behaviors and elevated weight status. This intervention will incorporate evidence-informed strategies targeting self-regulation into cognitive-behavioral treatment for maladaptive eating. Adolescents will use the app for 16 weeks and provide feedback on its usability and effectivene…

Not Yet Recruiting

NCT07685548 — AI-Driven Tumor Response Evaluation for Solid Tumors

StatusNot yet recruiting
PhaseN/A
SponsorShanghai Zhongshan Hospital
Enrollment6120
Study TypeOBSERVATIONAL
ConditionsSolid Tumor Cancer; Neoplasms; Hepatocellular Carcinoma
Interventions

Purpose: This study is developing and validating an artificial intelligence (AI)-driven system to evaluate tumor response using changes in total tumor volume. The goal is to determine whether this AI-based approach can better predict patient survival compared with the current standard method (RECIST), which relies on linear measurements of a few selected tumors.

Participants: The study include…

NCT07619547 — Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease

StatusNot yet recruiting
PhaseN/A
SponsorNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Enrollment100
Study TypeOBSERVATIONAL
ConditionsInflammatory Bowel Disease; Crohn’s Disease; Ulcerative Colitis

Background:

Inflammatory bowel disease (IBD) is a term used to describe disorders that cause long-term inflammation in the digestive tract. Symptoms include stomach pain, diarrhea, and bleeding. Crohn’s disease and ulcerative colitis are the 2 main types of IBD. Researchers want to conduct a natural history study to learn more about whether genetic factors can cause IBD; how immune cells contr…

NCT05722210 — Prevalence and Development of Liver Dysfunction in Hematopoietic Stem Cell Transplant

StatusNot yet recruiting
PhaseN/A
SponsorNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Enrollment500
Study TypeOBSERVATIONAL
ConditionsHematopoietic Stem Cell Transplant

Background:

Hematopoietic stem cell transplant (HSCT) is a common treatment for many cancers and other illnesses. But many people who have HSCT go on to develop liver dysfunction. Researchers want to know more about how and why this happens. In this natural history study, they will try to learn what factors lead to liver dysfunction; how underlying liver disease may affect the results of HSCT;…

NCT06221046 — Testing the Safety and Efficacy of a Novel Barrier Cream for the Treatment of Moisture Associated Skin Damage

StatusNot yet recruiting
PhaseN/A
SponsorScotiaderm
Enrollment60
Study TypeINTERVENTIONAL
ConditionsMoisture Associated Skin Damage; Incontinence Associated Dermatitis; Fecal Incontinence
Interventions;

Liquid stool and diarrhea are associated with an increased risk for moisture-associated skin damage (MASD), and clinical evidence suggests that exposure to liquid stool is associated with severe MASD and extensive erosion of affected skin. There are no known products on the market that treat fecal incontinence or MASD caused by fecal enzyme activity.

Scotiaderm has invented a novel barrier cre…

NCT07689201 — A Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and Pimitespib

StatusNot yet recruiting
PhasePhase 2
SponsorGlaxoSmithKline
Enrollment24
Study TypeINTERVENTIONAL
ConditionsGastrointestinal Neoplasms
Interventions

The goal of this study is to evaluate the study drug velzatinib (GSK6042981 / IDRX-42) to see whether velzatinib can shrink or control tumors and is safe and tolerated in Japan participants with gastrointestinal tumors (GIST) who progressed or were intolerant to standard therapies.

NCT07689539 — Trial of DN022150 Versus Chemotherapy in Previously Treated Advanced Pancreatic Cancer With KRAS G12D Mutation

StatusNot yet recruiting
PhasePhase 3
SponsorJiangxi Kvvit Pharmaceutical Co., Ltd.
Enrollment360
Study TypeINTERVENTIONAL
ConditionsPancreatic Cancer
Interventions;

This study plans to enroll participants with previously treated advanced pancreatic cancer and harbor centrally confirmed KRAS G12D mutation. Eligible participants will be randomized 1:1 to DN022150 Monotherapy or Investigator’s Choice Chemotherapy

NCT07690683 — Patients With Hepatocellular Carcinoma (HCC)

StatusNot yet recruiting
PhaseN/A
SponsorFondazione Policlinico Universitario Agostino Gemelli IRCCS
Enrollment52
Study TypeINTERVENTIONAL
ConditionsHepatocellular Carcinoma; Hepatocellular Cancer; Liver Diseases; Liver Cancer
Interventions;

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide and is frequently diagnosed at an advanced stage, resulting in limited therapeutic options. Despite the advances in immunotherapy, a substantial proportion of patients fail to respond adequately due to mechanisms of immune resistance. The gut microbiota plays a crucial role in modulating the respon…

Enrolling by Invitation

NCT06424769 — Improving Outcomes and Reducing Disparities for Patients With Inflammatory Bowel Disease Through Epidemiology and Enhanced Disease Management

StatusEnrolling by invitation
PhaseN/A
SponsorUniversity of North Carolina, Chapel Hill
Enrollment900
Study TypeINTERVENTIONAL
ConditionsInflammatory Bowel Diseases; Crohn Disease; Ulcerative Colitis; Colitis
Interventions;

The goal of this clinical trial is to learn whether IBD patients have better disease outcomes and feel more empowered to manage their condition if they have access to text messaging with their clinical team and if their symptoms are more regularly monitored through text-based surveys.

Researchers will compare participants who have access to text-based monitoring, communication and education to…

Completed Trials

NCT00004850 — Epidemiology, Infectivity and Natural History of Hepatitis C Virus Infection

StatusCompleted
PhaseN/A
SponsorNational Institutes of Health Clinical Center (CC)
Enrollment805
Study TypeOBSERVATIONAL
ConditionsHepatitis C; Hepatitis B

This study will evaluate hepatitis C virus (HCV) infection in blood donors who test positive for antibodies to this virus. Most HCV-infected people do not become ill and are not aware that they have hepatitis or have had it in the past. Some infected people recover completely, whereas others remain chronically infected. The study will try to define infectivity of anti-HCV positive individuals, …

NCT00040222 — Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer

StatusCompleted
PhaseN/A
SponsorNational Cancer Institute (NCI)
Enrollment377
Study TypeOBSERVATIONAL
ConditionsFamilial Ovarian Cancer; Familial Breast Cancer; BRCA1-associate Malignancies; BRCA2-associated Malignancies

Individuals and families with known or suspected syndromes that include breast, ovarian or genetically-related cancers are enrolled in this family study, which is a syndrome-specific sub-set of the long-standing DCEG Human Genetics Program umbrella family studies protocol (78-C-0039). Cancer outcomes are documented through review of medical, vital, and pathology records. Selected individuals an…

NCT01581554 — Withdrawal of Therapy After Long-Term Antiviral Treatment for Chronic Hepatitis B

StatusCompleted
PhaseN/A
SponsorNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Enrollment15
Study TypeOBSERVATIONAL
ConditionsChronic Hepatitis B e Antigen Positive; Chronic Hepatitis B e Antigen Negative

Background:

- Chronic infection with the hepatitis B virus may lead to cirrhosis, liver disease, and cancer of the liver. There is no cure for the infection, but several drugs have been approved to treat it. These drugs can keep the virus levels low. They seem to be safe for short-term use. But the drugs have not yet been approved for long-term use because some of them can have serious side e…

NCT01352962 — Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors

StatusCompleted
PhasePhase 1
SponsorNational Cancer Institute (NCI)
Enrollment18
Study TypeINTERVENTIONAL
ConditionsUrethral Neoplasms; Neoplasms, Urethral; Cancer of the Urethra; Urethral Cancer
Interventions; ;

Background:

- Gemcitabine and carboplatin are chemotherapy drugs used to treat several types of cancer, including cancer of the pancreas, bladder, ovaries, and lung. Lenalidomide, a drug that prevents the growth of new blood vessels in tumors, has been approved for treatment of certain blood cancers, but it has not yet been approved for use in combination with gemcitabine and carboplatin. Res…

NCT01387555 — A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib

StatusCompleted
PhasePhase 2
SponsorJennerex Biotherapeutics
Enrollment129
Study TypeINTERVENTIONAL
ConditionsHepatocellular Carcinoma; Liver Cancer; HCC
Interventions;

This study is to determine whether JX-594 (Pexa-Vec) plus best supportive care is more effective in improving survival than best supportive care in patients with advanced Hepatocellular Carcinoma (HCC) who have failed sorafenib.

NCT02190253 — Seroprevalence of Hepatitis E in People With an Organ Transplant

StatusCompleted
PhaseN/A
SponsorNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Enrollment447
Study TypeOBSERVATIONAL
ConditionsHepatitis E

Background:

- The hepatitis E virus causes an acute hepatitis that usually goes away by itself. Researchers in France studied people who received a liver or kidney transplant. They found that hepatitis E may not go away by itself in these people. It becomes chronic. This can cause serious liver disease. More than half the people who had organ transplant who had hepatitis E seemed to get a chr…

NCT03519997 — A Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma

StatusCompleted
PhasePhase 2
SponsorDavid Hsieh
Enrollment35
Study TypeINTERVENTIONAL
ConditionsHepatocellular Carcinoma
Interventions;

This is a non-randomized, open-label, multi-site phase II therapeutic trial of pembrolizumab and bavituximab in patients with locally advanced HCC. Locally advanced or metastatic HCC is defined as disease that is not amenable to surgical and/or locoregional therapies. Subjects must not have received prior systemic therapy for advanced HCC in keeping with the first-line setting of this study.

NCT03879109 — Chemotherapy Followed by Pelvic Reirradiation Versus Chemotherapy Alone as Pre-operative Treatment for Locally Recurrent Rectal Cancer

StatusCompleted
PhasePhase 3
SponsorUniversity Hospital, Bordeaux
Enrollment58
Study TypeINTERVENTIONAL
ConditionsRectal Cancer
Interventions; ;

GRECCAR 15 is focused on Locally Recurrent Rectal Cancer (LRRC) for patients with previous pelvic radiotherapy for the primary rectal cancer. This situation leads to a 20% higher risk of non-curative resection for the LRRC management (R1 status) impacting significantly the overall survival. The widespread use of neoadjuvant radiotherapy for primary rectal cancer introduces this new problem: the…

NCT04867954 — Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis

StatusCompleted
PhaseN/A
SponsorUniversity of Wisconsin, Madison
Enrollment84
Study TypeOBSERVATIONAL
ConditionsCirrhosis, Liver; Gastroesophageal Varices; Fontan Procedure
Interventions; ;

The goal of this research is to validate novel non-invasive Magnetic resonance imaging (MRI) biomarkers to detect Gastroesophageal varices (GEV) in patients with cirrhosis, including fractional flow change in the portal vein and elevated azygos flow.

End-stage liver disease (cirrhosis) is characterized by advanced fibrosis, liver failure, and portal hypertension. There are many causes of cirrh…

NCT05630820 — Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2)

StatusCompleted
PhasePhase 3
SponsorGlaxoSmithKline
Enrollment857
Study TypeINTERVENTIONAL
ConditionsChronic Hepatitis B; Hepatitis B, Chronic
Interventions;

This study is intended to confirm the efficacy, safety, pharmacokinetic (PK) profile, and the durability of hepatitis B virus surface antigen (HBsAg) suppression observed with bepirovirsen for 24 weeks (with loading doses) as compared to the placebo arm. This study will have 4 stages: a) Double-blind treatment (bepirovirsen or placebo) for 24 weeks. b) Nucleos(t)ide analogue (NA) treatment for …

NCT07689266 — Soluble Immune Checkpoints in Intra-Abdominal Infections

StatusCompleted
PhaseN/A
SponsorIstanbul Training and Research Hospital
Enrollment75
Study TypeOBSERVATIONAL
ConditionsIntra Abdominal Infections
Interventions

Intraabdominal infections is a life-threatening syndrome with a high incidence and a significant economic burden. The early-stage cytokine storm and the late-stage immunosuppression contribute to the mortality of sepsis. Immune checkpoints expressed on lymphocytes and antigen-presenting cells (APCs) play a crucial role in the pathogenesis of sepsis by regulating immune dysfunction. Specific the…

NCT06411756 — Physical Activity Centers Empowerment

StatusCompleted
PhaseN/A
SponsorUNC Lineberger Comprehensive Cancer Center
Enrollment21
Study TypeINTERVENTIONAL
ConditionsColorectal Neoplasms
Interventions; ;

This research study tests the feasibility of the Physical Activity Centers Empowerment (PACE) physical activity intervention for African American individuals diagnosed with colorectal cancer.

Feasibility will be measured as intervention reach, effectiveness, adoption, implementation, and maintenance. Seventy-two subjects will be recruited to conduct a pilot two-group, randomized repeated measu…

NCT07689123 — Evaluating the Outcome of Surgical Clip Versus Ligatures in Securing Base of Appendix in Laparoscopic Appendicectomy.

StatusCompleted
PhaseN/A
SponsorUniversiti Sains Malaysia
Enrollment64
Study TypeINTERVENTIONAL
ConditionsAppendicitis (Diagnosis)
Interventions;

The goal of this clinical trial is to evaluate the outcome of using surgical clip versus ligature to secure the base of appendix during laparoscopic appendicectomy. The main questions it aims to answer are to compare the post op complications. Compare the length of hospital stay and to compare the impact of cost.

Researches will compare the use of surgical clip versus a suture ligature. Partic…

Available Studies

NCT07689942 — Expanded Access to 0.5 mg eRapa for Familial Adenomatous Polyposis

StatusAvailable
PhaseN/A
SponsorBiodexa Pharmaceuticals
EnrollmentN/A
Study TypeEXPANDED_ACCESS
ConditionsFamilial Adenomatous Polyposis (FAP)
Interventions

This expanded access program provides 0.5 mg eRapa (encapsulated rapamycin) to patients with familial adenomatous polyposis (FAP) who have no satisfactory alternative treatment options and are not eligible to participate in a clinical trial. The objective is to provide access to eRapa based on the treating physician’s assessment that the potential benefits outweigh the potential risks, with app…

Other (Suspended)

NCT06174805 — AXIOS™ Gastroenterostomy for Gastric Outlet Obstruction IDE

StatusSuspended
PhaseN/A
SponsorBoston Scientific Corporation
Enrollment67
Study TypeINTERVENTIONAL
ConditionsGastric Outlet Obstruction
Interventions

To investigate the safety and technical success of EUS-guided gastroenterostomy (EUS-GE) using the AXIOSTM lumen-apposing Metal Stent for the management of symptoms associated with gastric outlet obstruction from malignant unresectable neoplasm.

NCT06557733 — An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous Polyposis

StatusSuspended
PhasePhase 2
SponsorNational Cancer Institute (NCI)
Enrollment38
Study TypeINTERVENTIONAL
ConditionsColorectal Carcinoma; Familial Adenomatous Polyposis
Interventions; ;

This open-label phase II trial tests how well TPST-1495 works in reducing the number of polyps in the small bowel and colon in patients with familial adenomatous polyposis (FAP). FAP is an inherited condition in which numerous polyps (growths that protrude from mucous membranes) form on the inside walls of the colon and rectum. It increases the risk for colon cancer. TPST-1495 binds to specific…